Assessing the Impact of COVID-19 on HMPV Incidence and Severity Among Adults

NCT ID: NCT06309212

Last Updated: 2024-03-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2197 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-12-15

Study Completion Date

2024-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Human metapneumovirus (HMPV) is primarily recognized as a childhood pathogen, but its impact on adults remains largely underestimated. This study investigates the prevalence, clinical characteristics, and post-COVID-19 trends of HMPV infection among adults in Istanbul, Turkey.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Human metapneumovirus (HMPV) is primarily recognized as a childhood pathogen, but its impact on adults remains largely underestimated. This study investigates the prevalence, clinical characteristics, and post-COVID-19 trends of HMPV infection among adults in Istanbul, Turkey.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

The Prevalance of HMPV After COVID-19 Pandemic The Importance of Accurate Diagnosis for HPMV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pre-COVID period

January 2016 to January 2020

Observation

Intervention Type OTHER

Analyse of data from adults with respiratory tract infections who were tested for various respiratory viruses using a multiplex PCR assay

Post-COVID period

January 2021 to September 2023

Observation

Intervention Type OTHER

Analyse of data from adults with respiratory tract infections who were tested for various respiratory viruses using a multiplex PCR assay

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Observation

Analyse of data from adults with respiratory tract infections who were tested for various respiratory viruses using a multiplex PCR assay

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults \>18 years
* Patients with acute respiratory tract infection symptoms
* Patients who underwent multiplex PCR testing for respiratory viruses

Exclusion Criteria

* Patients for whom no respiratory viral panel test was conducted
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Acibadem University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Acibadem University

Istanbul, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

References

Explore related publications, articles, or registry entries linked to this study.

Niederman MS, Torres A. Respiratory infections. Eur Respir Rev. 2022 Oct 19;31(166):220150. doi: 10.1183/16000617.0150-2022. Print 2022 Dec 31.

Reference Type BACKGROUND
PMID: 36261160 (View on PubMed)

Haas LE, Thijsen SF, van Elden L, Heemstra KA. Human metapneumovirus in adults. Viruses. 2013 Jan 8;5(1):87-110. doi: 10.3390/v5010087.

Reference Type BACKGROUND
PMID: 23299785 (View on PubMed)

Boivin G, De Serres G, Hamelin ME, Cote S, Argouin M, Tremblay G, Maranda-Aubut R, Sauvageau C, Ouakki M, Boulianne N, Couture C. An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility. Clin Infect Dis. 2007 May 1;44(9):1152-8. doi: 10.1086/513204. Epub 2007 Mar 28.

Reference Type BACKGROUND
PMID: 17407031 (View on PubMed)

Chow EJ, Uyeki TM, Chu HY. The effects of the COVID-19 pandemic on community respiratory virus activity. Nat Rev Microbiol. 2023 Mar;21(3):195-210. doi: 10.1038/s41579-022-00807-9. Epub 2022 Oct 17.

Reference Type BACKGROUND
PMID: 36253478 (View on PubMed)

Pearson V. Case studies. Baton Rouge puts community first. Trustee. 1995 May;48(5):24-6. No abstract available.

Reference Type BACKGROUND
PMID: 10142898 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-20/687

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Immunity With Acute Hepatits A
NCT06942962 NOT_YET_RECRUITING